Point72 Hong Kong LTD Biogen Inc. Call Options Transaction History

Point72 Hong Kong LTD

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $214,159 - $295,306	1,100 Added 37.93%	4,000 $1.07 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $375,080 - $446,040	-2,000 Reduced 40.82%	2,900 $591,000
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $426,294 - $537,108	2,200 Added 81.48%	4,900 $1.03 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $1.72 Million - $2.22 Million	-7,700 Reduced 74.04%	2,700 $648,000
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $622,578 - $811,910	-2,200 Reduced 17.46%	10,400 $2.94 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $3.26 Million - $5.23 Million	12,600 New	12,600 $4.36 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.